We will be comparing the differences between Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Aptose Biosciences Inc. (NASDAQ:APTO) as far as analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Regeneron Pharmaceuticals Inc.||354||4.63||N/A||20.54||14.84|
|Aptose Biosciences Inc.||2||0.00||N/A||-0.77||0.00|
In table 1 we can see Regeneron Pharmaceuticals Inc. and Aptose Biosciences Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 provides us the return on assets, return on equity and net margins of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Regeneron Pharmaceuticals Inc.||0.00%||29.2%||21.4%|
|Aptose Biosciences Inc.||0.00%||-182.8%||-152.7%|
Risk and Volatility
A 1.15 beta indicates that Regeneron Pharmaceuticals Inc. is 15.00% more volatile compared to Standard and Poor’s 500. Aptose Biosciences Inc.’s 61.00% more volatile than Standard and Poor’s 500 which is a result of the 1.61 beta.
The current Quick Ratio of Regeneron Pharmaceuticals Inc. is 4 while its Current Ratio is 4.6. Meanwhile, Aptose Biosciences Inc. has a Current Ratio of 5.9 while its Quick Ratio is 5.9. Aptose Biosciences Inc. is better positioned to pay off its short-term and long-term debts than Regeneron Pharmaceuticals Inc.
The Ratings and Recommendations for Regeneron Pharmaceuticals Inc. and Aptose Biosciences Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Regeneron Pharmaceuticals Inc.||0||3||1||2.25|
|Aptose Biosciences Inc.||0||0||2||3.00|
The upside potential is 39.47% for Regeneron Pharmaceuticals Inc. with consensus price target of $425.2. Competitively Aptose Biosciences Inc. has an average price target of $6, with potential upside of 124.72%. Based on the results delivered earlier, Aptose Biosciences Inc. is looking more favorable than Regeneron Pharmaceuticals Inc., analysts view.
Institutional & Insider Ownership
Roughly 73.9% of Regeneron Pharmaceuticals Inc. shares are held by institutional investors while 35.1% of Aptose Biosciences Inc. are owned by institutional investors. Insiders held 20% of Regeneron Pharmaceuticals Inc. shares. Competitively, insiders own roughly 20.4% of Aptose Biosciences Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Regeneron Pharmaceuticals Inc.||-2.83%||-3.73%||-10.57%||-27.42%||-17.97%||-18.4%|
|Aptose Biosciences Inc.||-6.67%||-4.55%||29.23%||22.93%||-12.8%||31.94%|
For the past year Regeneron Pharmaceuticals Inc. had bearish trend while Aptose Biosciences Inc. had bullish trend.
Regeneron Pharmaceuticals Inc. beats on 6 of the 10 factors Aptose Biosciences Inc.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.